GPI Valuation
Is GPI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GPI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GPI (€11.24) is trading below our estimate of fair value (€13.02)
Significantly Below Fair Value: GPI is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GPI?
Key metric: As GPI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is GPI's PE Ratio? | |
|---|---|
| PE Ratio | 36.2x |
| Earnings | €8.93m |
| Market Cap | €323.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 9.8x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does GPI's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17.8x | ||
GHC Garofalo Health Care | 25x | 11.0% | €522.5m |
ELN EL.En | 19x | 8.3% | €974.4m |
SRI Servizi Italia | 14.7x | 16.9% | €68.7m |
3733 Software Service | 12.5x | 9.1% | JP¥71.5b |
GPI GPI | 36.2x | 35.2% | €323.8m |
Price-To-Earnings vs Peers: GPI is expensive based on its Price-To-Earnings Ratio (36.2x) compared to the peer average (17.8x).
Price to Earnings Ratio vs Industry
How does GPI's PE Ratio compare vs other companies in the European Healthcare Services Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: GPI is expensive based on its Price-To-Earnings Ratio (36.2x) compared to the European Healthcare Services industry average (18.6x).
Price to Earnings Ratio vs Fair Ratio
What is GPI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 36.2x |
| Fair PE Ratio | 26.5x |
Price-To-Earnings vs Fair Ratio: GPI is expensive based on its Price-To-Earnings Ratio (36.2x) compared to the estimated Fair Price-To-Earnings Ratio (26.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.24 | €16.57 +47.4% | 11.3% | €19.10 | €14.60 | n/a | 3 |
| Nov ’25 | €11.82 | €16.57 +40.2% | 11.3% | €19.10 | €14.60 | n/a | 3 |
| Oct ’25 | €12.98 | €16.57 +27.6% | 11.3% | €19.10 | €14.60 | n/a | 3 |
| Sep ’25 | €12.00 | €16.37 +36.4% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| Aug ’25 | €12.06 | €16.37 +35.7% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| Jul ’25 | €12.40 | €16.37 +32.0% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| Jun ’25 | €12.30 | €16.37 +33.1% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| May ’25 | €12.52 | €16.30 +30.2% | 10.0% | €18.50 | €14.60 | n/a | 3 |
| Apr ’25 | €12.12 | €15.20 +25.4% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Mar ’25 | €11.36 | €15.20 +33.8% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Feb ’25 | €9.31 | €15.20 +63.3% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Jan ’25 | €9.97 | €15.20 +52.5% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Dec ’24 | €8.00 | €15.20 +90.0% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Nov ’24 | €7.53 | €15.20 +101.9% | 14.2% | €17.50 | €12.30 | €11.82 | 3 |
| Oct ’24 | €8.95 | €16.83 +88.1% | 4.4% | €17.50 | €15.80 | €12.98 | 3 |
| Sep ’24 | €9.84 | €16.83 +71.1% | 4.4% | €17.50 | €15.80 | €12.00 | 3 |
| Aug ’24 | €10.90 | €16.77 +53.8% | 4.1% | €17.30 | €15.80 | €12.06 | 3 |
| Jul ’24 | €11.70 | €16.77 +43.3% | 4.1% | €17.30 | €15.80 | €12.40 | 3 |
| Jun ’24 | €11.32 | €16.77 +48.1% | 4.1% | €17.30 | €15.80 | €12.30 | 3 |
| May ’24 | €12.12 | €17.33 +43.0% | 0.7% | €17.50 | €17.20 | €12.52 | 3 |
| Apr ’24 | €12.80 | €17.43 +36.2% | 0.5% | €17.50 | €17.30 | €12.12 | 3 |
| Mar ’24 | €13.26 | €17.63 +33.0% | 1.1% | €17.90 | €17.50 | €11.36 | 3 |
| Feb ’24 | €14.38 | €18.03 +25.4% | 4.2% | €19.10 | €17.50 | €9.31 | 3 |
| Jan ’24 | €14.46 | €18.03 +24.7% | 4.2% | €19.10 | €17.50 | €9.97 | 3 |
| Dec ’23 | €13.62 | €17.97 +31.9% | 4.5% | €19.10 | €17.30 | €8.00 | 3 |
| Nov ’23 | €13.40 | €18.47 +37.8% | 8.2% | €20.60 | €17.30 | €7.53 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Fresenius Medical Care
€12.4b
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
1FME
€42.31
7D
1.2%
1Y
18.1%
Amplifon
€5.2b
Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.
AMP
€23.24
7D
-2.1%
1Y
-18.2%
Garofalo Health Care
€522.5m
Operates healthcare clinics in Italy.
GHC
€5.90
7D
6.1%
1Y
29.7%